Market Overview

UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Share:
Related BIIB
Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS
Government Study: Cellphone Radiation Linked To Cancer
European Ad Comm backs expanded use of Biogen's Tysabri in RRMS patients (Seeking Alpha)

In a report published Thursday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $187.00 to $200.00.

In the report, Baral noted, “Reiterate BUY, increasing target to $200 on approval of Tecfidera (Tec), BIIB's new blockbuster potential oral MS drug with sparkling clean label. BIIB guidance implies strong confidence in the Tec launch. We have confidence in the initial phase of launch on high levels of community patient warehousing.We see long-term value and blockbuster potential in Tec, Tysabri and the hemophilia franchise. Our $200 price target is DCF-based.”

Biogen Idec closed on Wednesday at $182.68.

Latest Ratings for BIIB

DateFirmActionFromTo
Apr 2016Goldman SachsMaintainsNeutral
Apr 2016BMO CapitalInitiates Coverage onMarket Perform
Mar 2016BairdMaintainsNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!